ERY-TAB- erythromycin tablet, delayed release

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

Erythromycin (UNII: 63937KV33D) (Erythromycin - UNII:63937KV33D)

Pieejams no:

Carilion Materials Management

SNN (starptautisko nepatentēto nosaukumu):

Erythromycin

Kompozīcija:

Erythromycin 333 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ERY-TAB and other antibacterial drugs, ERY-TAB should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ® ® ERY-TAB tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: ® Upper respiratory tract infections of mild to moderate degree caused by ; ; (when used concomitantly with adequate doses of sulfonamides, since many strains of are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescr

Produktu pārskats:

NDC:68151-1174-1 in a PACKAGE of 1 TABLET, DELAYED RELEASES Store below 86°F (30°C).

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

ERY-TAB- ERYTHROMYCIN TABLET, DELAYED RELEASE
CARILION MATERIALS MANAGEMENT
----------
ERY-TAB (ERYTHROMYCIN DELAYED-RELEASE TABLETS, USP) ENTERIC-COATED
RX ONLY
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of ERY-TAB and
other antibacterial drugs, ERY-TAB should be used only to treat or
prevent infections that are proven
or strongly suspected to be caused by bacteria.
DESCRIPTION
ERY-TAB (erythromycin delayed-release tablets) is an antibacterial
product containing erythromycin
base in a specially enteric-coated tablet. The coating protects the
antibiotic from the inactivating effects
of gastric acidity and permits efficient absorption of the antibiotic
in the small intestine. ERY-TAB
tablets for oral administration are available in three dosage
strengths, each white oval tablet containing
either 250 mg, 333 mg, or 500 mg of erythromycin as the free base.
ERY-TAB tablets comply with
_USP Dissolution Test 1._
Erythromycin is produced by a strain of (formerly ) and belongs to the
macrolide group of antibiotics. It
is basic and readily forms salts with acids. Erythromycin is a white
to off-white powder, slightly
soluble in water, and soluble in alcohol, chloroform, and ether.
Erythromycin is known chemically as
(3R*, 4S*, 5S*, 6R*, 7R*, 9R*, 11R*, 12R*,13S*,
14R*)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α -
L-
-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihdroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-
(dimethylamino)-β-D-
-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione. The molecular
formula is
C H NO , and the molecular weight is 733.94. The structural formula
is: _Saccharopolyspora_
_erythraeaStreptomyces erythraeusriboxylo_
INACTIVE INGREDIENTS
®
®®
®®®
376713
Ammonium hydroxide, colloidal silicon dioxide, croscarmellose sodium,
crospovidone, diacetylated
monoglycerides, hydroxypropyl cellulose, hypromellose, hypromellose
phthalate, magnesium stearate,
microcrystalline cellulose, povidone, propylene glycol, sodium
citrate, sorbitan monooleate, talc, and
titanium dio